Open AccessGenetic polymorphisms of autophagy‐related gene 5 ( ATG5 ) rs473543 predict different disease‐free survivals of triple‐negative breast cancer patients receiving anthracycline‐ and/or taxane‐based adjuvant chemotherapy
Author(s) -
Li Meiying,
Ma Fei,
Wang Jiayu,
Li Qing,
Zhang Pin,
Yuan Peng,
Luo Yang,
Cai Ruigang,
Fan Ying,
Chen Shanshan,
Li Qiao,
Xu Binghe
Publication year - 2018
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1186/s40880-018-0268-1
Subject(s) - anthracycline , taxane , triple negative breast cancer , breast cancer , oncology , medicine , autophagy , adjuvant , disease , atg5 , chemotherapy , cancer , biology , genetics , apoptosis
Abstract Background Autophagy plays a crucial role in chemotherapy resistance of triple‐negative breast cancer (TNBC). Hence, autophagy‐related gene 5 (ATG5), an essential molecule involved in autophagy regulation, is presumably associated with recurrence of TNBC. This study was aimed to investigate the potential influence of single‐nucleotide polymorphisms in ATG5 on the disease‐free survival (DFS) of early‐stage TNBC patients treated with anthracycline‐ and/or taxane‐based chemotherapy. Methods We genotyped ATG5 SNP rs473543 in a cohort of 316 TNBC patients treated with anthracycline‐ and/or taxane‐based chemotherapy using the sequenom's MassARRAY system. Kaplan–Meier survival analysis and Cox proportional hazard regression analysis were used to analyze the association between ATG5 rs473543 genotypes and the clinical outcome of TNBC patients. Results Three genotypes, AA, GA, and GG, were detected in the rs473543 of ATG5 gene. The distribution of ATG5 rs473543 genotypes was significantly different between patients with and without recurrence ( P = 0.024). Kaplan–Meier survival analysis showed that patients carrying A allele of ATG5 rs473543 had an increased risk of recurrence and shorter DFS compared with those carrying the variant genotype GG in rs473543 ( P = 0.034). In addition, after adjusting for clinical factors, multivariate Cox regression analyses revealed that the AA/GA genotype of rs473543 was an independent predictor for DFS (hazard risk [HR], 1.73; 95% confidence interval [CI], 1.04–2.87; P = 0.034). In addition, DFS was shorter in node‐negative patients with the presence of A allele (AA/GA) than in those with the absence of A allele ( P = 0.027). Conclusion ATG5 rs473543 genotypes may serve as a potential marker for predicting recurrence of early‐stage TNBC patients who received anthracycline‐and/or taxane‐based regimens as adjuvant chemotherapy.